TG Therapeutics (TGTX) Reports Results from Ongoing Phase 2 Study of TG-1101 in Patients with MS at ECTRIMS - ACTRIMS
Tweet Send to a Friend
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced additional results from the Phase 2 multicenter trial of TG-1101 (ublituximab), the Company’s ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
